Haemophilia A management with emicizumab: A survey of haematologists in the United States

Patel Anisha M.; Owens Wendy E.; Poulos Kathleen; Raimundo Karina; Wong Gabriel; Bernard Janet; Powers Janet; Ko Richard H.

doi:10.2478/jhp-2021-0017

The Journal of Haemophilia Practice (Mar 2022)

Haemophilia A management with emicizumab: A survey of haematologists in the United States

Patel Anisha M.,
Owens Wendy E.,
Poulos Kathleen,
Raimundo Karina,
Wong Gabriel,
Bernard Janet,
Powers Janet,
Ko Richard H.

Affiliations

Patel Anisha M.: Genentech, Inc., South San Francisco, CA, USA
Owens Wendy E.: Genentech, Inc., South San Francisco, CA, USA
Poulos Kathleen: MedPanel, Waltham, MA, USA ; New affiliation: Ferrum Health, Inc., San Francisco, CA, USA
Raimundo Karina: Genentech, Inc., South San Francisco, CA, USA
Wong Gabriel: Genentech, Inc., South San Francisco, CA, USA; New affiliation:Seagen Inc., San Francisco, CA, USA
Bernard Janet: JANET BERNARD MedPanel, Waltham, MA, USA
Powers Janet: MedPanel, Waltham, MA, USA
Ko Richard H.: Genentech, Inc., South San Francisco, CA, USA

DOI: https://doi.org/10.2478/jhp-2021-0017
Journal volume & issue: Vol. 8, no. 1
pp. 155 – 182

Abstract

Read online

Emicizumab is a bispecific monoclonal antibody approved in the United States (US) for the treatment of people with haemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors. Changes to haematologists’ practices since the approval of emicizumab are of interest to the haemophilia A community.

Published in The Journal of Haemophilia Practice

ISSN: 2055-3390 (Online)
Publisher: Sciendo
Country of publisher: Poland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: https://sciendo.com/journal/JHP?tab=-aims-scope

About the journal

Abstract

Keywords